139 related articles for article (PubMed ID: 30931110)
1. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report.
Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M
Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110
[TBL] [Abstract][Full Text] [Related]
2. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report.
Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M
Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study.
Igarashi T; Yamada S; Hoshino Y; Murotani K; Baba H; Takami H; Yoshioka I; Shibuya K; Kodera Y; Fujii T
Ann Gastroenterol Surg; 2023 Jan; 7(1):157-166. PubMed ID: 36643365
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.
Takano N; Yamada S; Hirakawa A; Yokoyama Y; Kawashima H; Maeda O; Okada T; Ohno E; Yamaguchi J; Ishikawa T; Sonohara F; Suenaga M; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Fujii T; Kodera Y
Nagoya J Med Sci; 2019 May; 81(2):233-239. PubMed ID: 31239592
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel.
Umezawa R; Mizuma M; Nakagawa K; Yamamoto T; Takahashi N; Suzuki Y; Kishida K; Omata S; Unno M; Jingu K
Pancreatology; 2023 Sep; 23(6):650-656. PubMed ID: 37453848
[TBL] [Abstract][Full Text] [Related]
6. Splenic artery transposition for hepatic arterial reconstruction in conversion surgery of an initially unresectable, locally advanced pancreatic cancer after gemcitabine/nab-paclitaxel: A case report.
Tanaka H; Imai H; Higashi T; Murase K; Matsuhashi N; Yoshida K
Int J Surg Case Rep; 2021 Jan; 78():192-196. PubMed ID: 33360334
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of gemcitabine plus S-1
Zhu Z; Tang H; Ying J; Cheng Y; Wang X; Wang Y; Bai C
Cancer Biol Med; 2023 Aug; 20(10):765-78. PubMed ID: 37646237
[TBL] [Abstract][Full Text] [Related]
8. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case report.
Watanabe Y; Tatsuguchi T; Date K; Shinkawa T; Kuga H; Tamiya S; Nishihara K; Nakano T
J Med Case Rep; 2024 Jan; 18(1):13. PubMed ID: 38200536
[TBL] [Abstract][Full Text] [Related]
9. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer.
Takada R; Ikezawa K; Daiku K; Maeda S; Abe Y; Urabe M; Kai Y; Yamai T; Fukutake N; Nakabori T; Uehara H; Ashida R; Akita H; Takahashi H; Teshima T; Ohkawa K
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572960
[TBL] [Abstract][Full Text] [Related]
10. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report.
Ariake K; Motoi F; Mizuma M; Murakami K; Takadate T; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Nakagawa K; Sakata N; Morikawa T; Maeda S; Naitoh T; Egawa S; Unno M
Surg Case Rep; 2017 Dec; 3(1):15. PubMed ID: 28101795
[TBL] [Abstract][Full Text] [Related]
11. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
[TBL] [Abstract][Full Text] [Related]
12. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Drug-Induced Pneumomediastinum Preceding Interstitial Pneumonitis Onset during Treatment with a First-Line Regimen of GnP in a Patient with Unresectable Pancreatic Cancer].
Minamoto K; Ikeda T; Araki K; Hamada M
Gan To Kagaku Ryoho; 2022 Jul; 49(7):779-782. PubMed ID: 35851350
[TBL] [Abstract][Full Text] [Related]
14. [A Case of Locally Advanced, Unresectable Pancreatic Cancer with Superior Mesenteric Artery Invasion Treated with FOLFIRINOX plus Radiation Therapy, followed by Conversion Surgery].
Tani H; Kato H; Asano Y; Ito M; Arakawa S; Shimura M; Koike D; Ochi T; Kamio K; Kawai T; Yasuoka H; Higashiguchi T; Kunimura Y; Horiguchi K; Nagata H; Kondo Y; Kato Y; Hanai T; Sato H; Horiguchi A
Gan To Kagaku Ryoho; 2023 Aug; 50(8):929-932. PubMed ID: 37608424
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
[TBL] [Abstract][Full Text] [Related]
16. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
Cancer Diagn Progn; 2021; 1(5):399-409. PubMed ID: 35403152
[TBL] [Abstract][Full Text] [Related]
18. [Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable Pancreatic Cancer].
Tsujie M; Fumita S; Ishikawa H; Kitani K; Satoi S; Fukuda S; Manabe H; Akashi Y; Wakasa T; Shiono H; Tamura T; Yukawa M; Inoue M
Gan To Kagaku Ryoho; 2019 Aug; 46(8):1259-1263. PubMed ID: 31501367
[TBL] [Abstract][Full Text] [Related]
19. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology.
Igarashi T; Fukasawa M; Watanabe T; Kimura N; Itoh A; Tanaka H; Shibuya K; Yoshioka I; Hirabayashi K; Fujii T
Ann Gastroenterol Surg; 2024 Jan; 8(1):124-132. PubMed ID: 38250680
[TBL] [Abstract][Full Text] [Related]
20. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
